CAR-T Related Proteins
High-quality CAR-T target proteins for immunotherapy research, antibody screening, and affinity studies.
CAR-T Cell Therapy Target Proteins
Chimeric antigen receptor T (CAR-T) cells, which are genetically engineered to express specific synthetic antigen receptors, can specifically target antigens and kill tumor cells. CAR-T cells are capable of specifically recognizing their target antigen through the single-chain fragment variable (scFv) binding domain, resulting in T cell activation in a major histocompatibility complex (MHC)-independent manner.
Chemsis offers recombinant proteins, covering most of the investigational CAR-T cell therapy targets. We also provides biotinylated and fluorescent-label proteins to support your scientific research.
Recombinant proteins can be used for a variety of purposes for CAR-T cell research. We provide biotin and PE-labeled versions of many of the target antigens for CARs, such as BCMA, CD19, CD22, CD38, CD123, and ROR1. These PE-labeled proteins can bind to CAR-T cells and be detected by flow cytometry, in order to verify CAR-T cell antigen recognition.
Engineering T cells using a chimeric antigen receptor (CAR) to boost specific immune cell killing has made significant progress in the treatment of some cancer types. CAR-T cell therapy may also have potential benefits beyond cancer treatment, including treatments for infectious and chronic inflammatory diseases such as hepatitis, HIV/AIDS, lupus, and arthritis.
Featured CAR-T Targets
| BCMA | CD7 | CD19 |
| CD20 | CD30 | CLEC12A |
| EGFR | EGFRvIII | FAP |
| GPC3 | MSLN | Nectin-4 |
| PSMA | CD70 | FOLR1 |
| NKG2D | PD-L1 | ROR1 |
| SIRP Alph |
